Honokiol suppresses renal cancer cells' metastasis Via dual-blocking epithelial-mesenchymal transition and cancer stem cell properties through modulating miR-141/ZEB2 signaling

Molecules and Cells

Volumn 37, Issue 5, 2014, Pages 383-388

  Li, Weidong ^a   Wang, Qian ^b   Su, Qiaozhen ^c   Ma, Dandan ^c   An, Chang ^c   Ma, Lei ^a   Liang, Hongfeng ^c  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b JINAN UNIVERSITY   (China)

^c GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Cancer stem cell; Epithelial mesenchymal transition; Honokiol, microRNA; Renal cell carcinoma

Indexed keywords

CELL PROTEIN; HONOKIOL; MICRORNA 141; PROTEIN ZEB2; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIPHENYL DERIVATIVE; HOMEODOMAIN PROTEIN; LIGNAN; MICRORNA; MIRN141 MICRORNA, HUMAN; REPRESSOR PROTEIN; ZEB2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER STEM CELL; CANCER SURVIVAL; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IN VIVO STUDY; KIDNEY CARCINOMA; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; DRUG EFFECTS; KIDNEY NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIPHENYL COMPOUNDS; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; HOMEODOMAIN PROTEINS; HUMANS; KIDNEY NEOPLASMS; LIGNANS; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; NEOPLASTIC STEM CELLS; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; TUMOR BURDEN;

EID: 84901408401     PISSN: 10168478     EISSN: 02191032     Source Type: Journal    
DOI: 10.14348/molcells.2014.0009     Document Type: Article

References (38)

1. Addla, S.K., Brown, M.D., Hart, C.A., Ramani, V.A., and Clarke, N.W. (2008). Characterization of the Hoechst 33342 side population from normal and malignant human renal epithelial cells. Am. J. Physiol. Renal Physiol. 295, F680-687.
2. Ambros, V. (2004). The functions of animal microRNAs. Nature 431, 350-355.
3. Banerjee, P., Basu, A., Arbiser, J.L., and Pal, S. (2013). The natural product honokiol inhibits calcineurin inhibitor-induced and Ras-mediated tumor promoting pathways. Cancer Lett. 338, 292-299.
4. Cheng, L., Zhang, S., MacLennan, G.T., Lopez-Beltran, A., and Montironi, R. (2009). Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms. Hum. Pathol. 40, 10-29.
5. Croce, C.M., and Calin, G.A. (2005). miRNAs, cancer, and stem cell division. Cell 122, 6-7. (Pubitemid 40977933)
6. Deng, X., Ma, L., Wu, M., Zhang, G., Jin, C., Guo, Y., and Liu, R. (2013). miR-124 radiosensitizes human glioma cells by targeting CDK4. J. Neurooncol. 114, 263-274.
7. Fang, Y., Wei, J., Cao, J., Zhao, H., Liao, B., Qiu, S., Wang, D., Luo, J., and Chen, W. (2013). Protein expression of ZEB2 in renal cell carcinoma and its prognostic significance in patient survival. PLoS One 8, e62558.
8. Fried, L.E., and Arbiser, J.L. (2009). Honokiol, a multifunctional antiangiogenic and antitumor agent. Antioxid. Redox Signal. 11, 1139-1148.
9. Gregory, P.A., Bracken, C.P., Bert, A.G., and Goodall, G.J. (2008). MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle 7, 3112-3118.
10. Gupta, P.B., Onder, T.T., Jiang, G., Tao, K., Kuperwasser, C., Weinberg, R.A., and Lander, E.S. (2009). Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138, 645-659.
11. Henrion, M., Frampton, M., Scelo, G., Purdue, M., Ye, Y., Broderick, P., Ritchie, A., Kaplan, R., Meade, A., McKay, J., et al. (2013). Common variation at 2q22.3 (ZEB2) influences the risk of renal cancer. Hum. Mol. Genet. 22, 825-831.
12. Huang, B., Huang, Y.J., Yao, Z.J., Chen, X., Guo, S.J., Mao, X.P., Wang, D.H., Chen, J.X., and Qiu, S.P. (2013). Cancer stem cell-like side population cells in clear cell renal cell carcinoma cell line 769P. PLoS One 8, e68293.
13. Kong, D., Li, Y., Wang, Z., and Sarkar, F.H. (2011). Cancer stem cells and epithelial-to-mesenchymal transition (EMT)-phenotypic cells: are they cousins or twins? Cancers 3, 716-729.
14. Kumar, A., Kumar Singh, U., and Chaudhary, A. (2013). Honokiol analogs: a novel class of anticancer agents targeting cell signaling pathways and other bioactivities. Future Med. Chem. 5, 809-829.
15. Lee, Y.J., Lee, Y.M., Lee, C.K., Jung, J.K., Han, S.B., and Hong, J.T. (2011). Therapeutic applications of compounds in the Magnolia family. Pharmacol. Ther. 130, 157-176.
16. Liu, H., Zang, C., Emde, A., Planas-Silva, M.D., Rosche, M., Kuhnl, A., Schulz, C.O., Elstner, E., Possinger, K., and Eucker, J. (2008). Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer. Eur. J. Pharmacol. 591, 43-51.
17. Ma, L., Zhang, G., Miao, X.B., Deng, X.B., Wu, Y., Liu, Y., Jin, Z.R., Li, X.Q., Liu, Q.Z., Sun, D.X., et al. (2013). Cancer stem-like cell properties are regulated by EGFR/AKT/beta-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma. FEBS J. 280, 2027-2041.
18. Mani, S.A., Guo, W., Liao, M.J., Eaton, E.N., Ayyanan, A., Zhou, A.Y., Brooks, M., Reinhard, F., Zhang, C.C., Shipitsin, M., et al. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715. (Pubitemid 351636299)
19. McLaughlin, J.K., Lipworth, L., and Tarone, R.E. (2006). Epidemiologic aspects of renal cell carcinoma. Semin. Oncol. 33, 527-533. (Pubitemid 44511980)
20. Motzer, R.J., Mazumdar, M., Bacik, J., Berg, W., Amsterdam, A., and Ferrara, J. (1999). Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17, 2530-2540. (Pubitemid 29368255)
21. Moutasim, K.A., Nystrom, M.L., and Thomas, G.J. (2011). Cell migration and invasion assays. Methods Mol. Biol. 731, 333-343.
22. Nakada, C., Matsuura, K., Tsukamoto, Y., Tanigawa, M., Yoshimoto, T., Narimatsu, T., Nguyen, L.T., Hijiya, N., Uchida, T., Sato, F., et al. (2008). Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. J. Pathol. 216, 418-427.
23. Newman, D.J., Cragg, G.M., and Snader, K.M. (2003). Natural products as sources of new drugs over the period 1981-2002. J. Nat. Products 66, 1022-1037. (Pubitemid 36909859)
24. Oates, J.E., Grey, B.R., Addla, S.K., Samuel, J.D., Hart, C.A., Ramani, V.A., Brown, M.D., and Clarke, N.W. (2009). Hoechst 33342 side population identification is a conserved and unified mechanism in urological cancers. Stem Cells Dev. 18, 1515-1522.
25. Polyak, K., and Weinberg, R.A. (2009). Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 9, 265-273.
26. Ponnurangam, S., Mammen, J.M., Ramalingam, S., He, Z., Zhang, Y., Umar, S., Subramaniam, D., and Anant, S. (2012). Honokiol in combination with radiation targets notch signaling to inhibit colon cancer stem cells. Mol. Cancer Ther. 11, 963-972.
27. Radisky, D.C., and LaBarge, M.A. (2008). Epithelial-mesenchymal transition and the stem cell phenotype. Cell Stem Cell 2, 511-512. (Pubitemid 351729219)
28. Redova, M., Poprach, A., Besse, A., Iliev, R., Nekvindova, J., Lakomy, R., Radova, L., Svoboda, M., Dolezel, J., Vyzula, R., et al. (2013). MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma. Tumour Biol. 34, 481-491.
29. Roy, S.S., Gonugunta, V.K., Bandyopadhyay, A., Rao, M.K., Goodall, G.J., Sun, L.Z., Tekmal, R.R., and Vadlamudi, R.K. (2013). Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer. Oncogene [Epub ahead of print].
30. Singh, T., Prasad, R., and Katiyar, S.K. (2013). Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo. Epigenetics 8, 54-65.
31. Taube, J.H., Malouf, G.G., Lu, E., Sphyris, N., Vijay, V., Ramachandran, P.P., Ueno, K.R., Gaur, S., Nicoloso, M.S., Rossi, S., et al. (2013). Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell properties. Sci. Rep. 3, 2687.
32. Tian, W., Xu, D., and Deng, Y.C. (2012). Honokiol, a multifunctional tumor cell death inducer. Die Pharmazie 67, 811-816.
33. Valster, A., Tran, N.L., Nakada, M., Berens, M.E., Chan, A.Y., and Symons, M. (2005). Cell migration and invasion assays. Methods 37, 208-215. (Pubitemid 41587431)
34. Wotschofsky, Z., Liep, J., Meyer, H.A., Jung, M., Wagner, I., Disch, A.C., Schaser, K.D., Melcher, I., Kilic, E., Busch, J., et al. (2012). Identification of metastamirs as metastasis-associated micro-RNAs in clear cell renal cell carcinomas. Int. J. Biol. Sci. 8, 1363-1374.
35. Xie, Y.K., Huo, S.F., Zhang, G., Zhang, F., Lian, Z.P., Tang, X.L., and Jin, C. (2012). CDA-2 induces cell differentiation through suppressing Twist/SLUG signaling via miR-124 in glioma. J. Neurooncol. 110, 179-186.
36. Xu, H., Mei, Q., Xiong, C., and Zhao, J. (2013). Tumor-suppressing effects of miR-141 in human osteosarcoma. Cell Biochem. Biophys. [Epub ahead of print].
37. Yao, C.J., Lai, G.M., Yeh, C.T., Lai, M.T., Shih, P.H., Chao, W.J., Whang-Peng, J., Chuang, S.E., and Lai, T.Y. (2013). Honokiol eliminates human oral cancer stem-like cells accompanied with suppression of Wnt/ beta -catenin signaling and apoptosis induction. Evid. Based Complement. Alternat. Med. 2013, 146136.
38. Yoshino, H., Enokida, H., Itesako, T., Tatarano, S., Kinoshita, T., Fuse, M., Kojima, S., Nakagawa, M., and Seki, N. (2013). Epithelial-mesenchymal transition-related microRNA-200s regulate molecular targets and pathways in renal cell carcinoma. J. Hum. Genet. 58, 508-516.